Trial Profile

Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 16 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BIIB 063 (Primary) ; BIIB 063 (Primary)
Indications Sjogren's syndrome
Focus Adverse reactions; First in man; Pharmacodynamics
Sponsors Biogen

Most Recent Events

08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
17 Apr 2017 Status changed from suspended to discontinued due to pending additional preclinical safety findings in non-human primates.
24 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com